1975 Bachelor of Arts, Zoology, Indiana University
1980 Doctor of Medicine, University of Vermont College of Medicine
1980-1983 Intern/Resident of Internal Medicine, Fletcher Allen Health Care, Burlington, VT
1983-1985 Oncology Fellowship, Wisconsin Clinical Cancer Center
1985-1986 Research Associate, Wisconsin Clinical Cancer Center
1983 Internal Medicine
1985 Medical Oncology
Alliance member/researcher since 1992
American Society of Clinical Oncology (ASCO)National Cancer Institute, research since 1988
Clinical Practice Committee, member since 2000
ASCO, Advisor to Relative Value Up-date Committee, 2009-2010
ASCO, Deligate to the American Medical Associate, since 2010
Statesman Award 2011
Received designation as Fellow of ASCO 2012
Chair, Clinical Practice Cimmittee Workgroup: Practice Policy and Emerging Issues, 2012
Vermont State Medical Society, council since 2000
Northern New England Clinical Oncology Society – President 2007, 2001 and member since 1990
Chris returned to Burlington in 1986 to start his Oncology practice –Vermont Center for Cancer Medicine (VCCM), and teach at Fletcher Allen Health Care. He started and received funding for the oncology research program at Fanny Allen Hospital. His former practice (Vermont Center for Cancer Medicine) grew to four physicians and two nurse practitioners practicing in St Albans, Middlebury and Burlington/Colchester and served over 22,000 patients in Vermont and upper New York for over 27 years. He served on the board of trustees when the Fanny Allen Hospital merged with Medical Center Hospital of Vermont to form Fletcher Allen Health Care (FAHC). He was a founding member of the Breast Cancer Center at FAHC. He served on the initial committee to fund and build the first in house hospice program in Vermont – the Vermont Respite House, and served on the original board of directors. He worked diligently on Access to Care, especially for patients in rural areas of Northern New England and published his work on March 2010. The ability to collect data and interact with colleagues from small rural hospitals as well as FAHC, Dartmouth Hitchcock Medical Center, and Maine Medical Center was inspiring and continues to motivate him. The study revealed that overall the care provided in rural areas was comparable in many ways to that provided in urban areas. However, the infrastructure to provide excellent care in rural areas is fragile and being threatened. Maintaining this is still his passion. On October 1, 2013 Chris joined Vermont Cancer Center as associate professor in Oncology at FAHC so that he can continue his passion for providing compassionate and quality care to his patients and pursue his interest to maintain access to state of the art cancer care in rural environments.
Nunnink JC, Chuang AH, Bresnick E. The ontogeny of nuclear aryl hydrocarbon hydroxylase. Chemico-biological interactions. 1978 Sep; 22(2-3): 225-30.
Carbone PP Nunnink JC. Aspergillosis infection following radiotherapy. New York state journal of medicine. 1984 Sep; 84(9):434-5.
Nunnink JC, Krusinski PA, Yates JW. Multicentric reticulohistiocytosis and cancer: a case report and review of the literature. Medical and pediatric oncology. 1985; 13(5): 273-9.
Nunnink JC, Gallagher JG, Yates JW. Legionnaires' disease in patients with cancer. Medical and pediatric oncology. 1986; 14(2): 81-5.
Wood, ME, Phillips, GK, et. al. Hematology/Oncology Secrets: Chapter 43: GI complications of chemotherapy. 3rd edition, Hanley & Belfus, 2003.
Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, et al. Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Jan; 15(1):355-60.
Johnson, A. and Nunnink, JC, et al. Oncology Care in Rural New England, Journal of Oncology Practice, vol 6, issue 2, 2010 March: 81-89.